{"id":18576,"date":"2025-03-20T09:42:25","date_gmt":"2025-03-20T09:42:25","guid":{"rendered":"https:\/\/theprivateclinic.me\/?p=18576"},"modified":"2025-03-20T09:42:25","modified_gmt":"2025-03-20T09:42:25","slug":"optimizing-likelihood-of-treatment-for-postpartum-depression-assessment-of-barriers-to-care","status":"publish","type":"post","link":"https:\/\/theprivateclinic.me\/ar\/posts\/mental-health\/optimizing-likelihood-of-treatment-for-postpartum-depression-assessment-of-barriers-to-care\/","title":{"rendered":"Optimizing Likelihood of Treatment for Postpartum Depression: Assessment of Barriers to Care"},"content":{"rendered":"Summarize \u2728 \u062a\u0644\u062e\u064a\u0635<\/a>


\n<\/p>\n

\n

Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women\u2019s Mental Health at Massachusetts General Hospital, recently shared his insights on optimizing the likelihood of treatment for postpartum depression<\/a> with Ob.Gyn News on August 27, 2024.<\/a><\/em><\/p>\n\n

\u00a0<\/p>\n

I have written in my first\u00a0two<\/a><\/span>\u00a0<\/span>columns<\/span><\/a><\/span><\/span>\u00a0of 2024 about how the obstacles for women to access perinatal mental healthcare are not well understood. This is despite an almost uniform adoption of screening practices for postpartum depression<\/a> (PPD) over the last 10-15 years in the United States, the approval and off-label use of effective pharmacologic and nonpharmacologic treatments for PPD, and the growing numbers of perinatal access programs across the country in various states and hospitals.<\/span><\/p>\n

I want to revisit this topic because I believe it is extremely important that we get to a better understanding of the obstacles postpartum patients experience so we can flatten the curve with respect to the perinatal treatment cascade. It turns out that screening is easy but accessing care for those with a positive screen with significant depressive symptoms is an entirely distinct outcome.<\/span><\/p>\n

Recently, a group of investigators\u00a0examined<\/a><\/span>\u00a0<\/span>the barriers to identifying and treating women for PPD. In a meta-analysis that included 32 reviews, the researchers analyzed the barriers women face when they seek help, access care, and engage in treatment for mental health issues while pregnant or in the postpartum period. The researchers found women have a wide variety of barriers to seeking and accessing care related to societal, political, organizational, interpersonal, healthcare professional, and individual factors at every level of the care pathway. In total, the researchers categorized barriers into six overarching themes and 62 sub-themes, and I want to highlight a few of the biggest contributors below.<\/span><\/p>\n

In the meta-analysis, a major contributor to deciding to consult with a healthcare professional was a lack of understanding of what constituted a perinatal mental illness. This lack of understanding led women to ignore or minimize their symptoms. Others said that the cost of travel or arranging childcare were factors that prevented them from making an appointment with a provider. Some women reported that their healthcare professionals\u2019 normalization of their symptoms was a barrier in the early stages of the care pathway, and others were unclear about the role a healthcare professional played in involving social services and removing their child from their care, or feared being judged as a bad mom.<\/span><\/p>\n

One of the major societal factors identified in the study is the stigma associated with PPD. It is unfortunate that for so many postpartum patients, an extraordinary stigma associated with PPD still persists despite efforts from a large number of stakeholders, including the scientific community, advocacy groups, and celebrities who have publicly come out and described their experiences with PPD. For so many postpartum patients, there is an inability to let go of the stigma, shame, humiliation, and isolation associated with the suffering that goes along with PPD.<\/span><\/p>\n

Another factor identified in the study as being an obstacle to care was a lack of a network to help postpartum patients navigate the shifting roles associated with new parenthood, which is magnified if a patient has developed major depressive disorder. This is why a strong social support network is critical to help women navigate the novelty of being a new mom. We were aware of this as a field nearly 30 years ago when Michael W. O\u2019Hara, PhD,\u00a0published<\/a><\/span>\u00a0<\/span>a paper in the\u00a0Archives of General Psychiatry<\/em>\u00a0noting that social support was an important predictor for risk of PPD.<\/span><\/p>\n

When we talk with patients in clinic, and even when we interviewed subjects for our upcoming\u00a0documentary<\/span>\u00a0<\/span>More Than Blue<\/em>, which will be completed in the fall of 2024, women in the postpartum period have cited the navigation of our current healthcare system as one of the greatest obstacles to getting care. Suffering from PPD and being handed a book of potential providers, absent someone helping to navigate that referral system, is really asking a new mom to climb a very tall mountain. Additionally, moms living in rural areas likely don\u2019t have the sort of access to perinatal mental health services that women in more urban areas do.<\/span><\/p>\n

It becomes increasingly clear that it is not the lack of availability of effective treatments that is the problem. As I\u2019ve mentioned in previous columns, the last 15 years has given us a much greater understanding of the effectiveness of antidepressants as well as nonpharmacologic psychotherapies for women who may not want to be on a medicine. We now have very effective psychotherapies and there\u2019s excitement about other new treatments that may have a role in the treatment of postpartum depression<\/a>, including the use of neurosteroids, ketamine or esketamine, and psychedelics or neuromodulation such as transcranial magnetic stimulation. There is also no dearth of both well-studied treatments and even new and effective treatments that, as we move toward precision reproductive psychiatry, may be useful in tailoring treatment for patients.<\/span><\/p>\n

\n
\n
\n
\n

If we\u2019re looking to understand the anatomy of the perinatal treatment cascade, finally systematically evaluating these barriers may lead us down a path to understand how to build the bridge to postpartum wellness for women who are suffering. While what\u2019s on the horizon is very exciting, we still have yet to address these barriers that prevent women from accessing this expanding array of treatment options. That is, in fact, the challenge to patients, their families, advocacy groups, political organizations, and society in general. The bridging of that gap is a burden that we all share as we try to mitigate the suffering associated with such an exquisitely treatable illness while access to treatment still feels beyond reach of so many postpartum persons around us.<\/span><\/span><\/p>\n

As we continue our research on new treatments, we should keep in mind that they will be of no value unless we understand how to facilitate access to these treatments for the greatest number of patients. This endeavor really highlights the importance of health services research and implementation science, and that we need to be partnering early and often with colleagues if we are to truly achieve this goal.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

Dr. Cohen is the director of the Ammon-Pinizzotto Center for Women\u2019s Mental Health at Massachusetts General Hospital (MGH) in Boston, which provides information resources and conducts clinical care and research in reproductive mental health. He has been a consultant to manufacturers of psychiatric medications. STEPS for PPD is funded by the Marriott Foundation. Full disclosure information for Dr. Cohen is available at womensmentalhealth.org. Email Dr. Cohen at\u00a0 obnews@mdedge.com.<\/em><\/p>\n

\n

Related Posts<\/h3>\n